Clostridioides difficile (C. diff) intestinal infections can cause severe, debilitating diarrhea in patients who are hospitalized or on immunosuppressive therapies. The infections can be very hard to eradicate, roaring back when patients try to taper their antibiotics. Many people wind up on antibiotics for months and can become resistant to three or more of them.

"Often being on antibiotics isn't sufficient," explained the author. "The infection can catalyze severe, runaway inflammation, especially in patients with inflammatory bowel disease."

This inflammation, in turn, promotes C. diff colonization of intestinal tissue. And antibiotics themselves could be part of the problem.

"Once we attack C. diff with antibiotics, it disrupts the gut microbiome," said the senior author. "That creates an opportunity for severe, recurring infection, and it becomes a vicious cycle."

A potential new approach described in the journal Nature—focuses on curbing intestinal inflammation rather than fighting the bacteria directly.

Instead of antibiotics, the approach could employ drugs that are already in use for nausea and migraine.

The drugs worked in mice with a hypervirulent strain of C. diff. The authors hope to develop a clinical trial to test these agents in people with C. diff infections.

Using single-cell RNA sequencing data and other techniques, the lab worked out the mechanism, showing that toxin B binds to specific receptors (FZD1/2/7 and CSPG4).

They further showed that two key cell types in gut tissues—sensory neurons and pericytes, respectively—sport these receptors at especially high levels.

The authors found that in response to the toxin, the sensory neurons secrete neuropeptides called substance P and calcitonin gene-related peptide (CGRP), while the pericytes, which surround blood vessels, produce pro-inflammatory cytokines.

In a mouse model, this drove intense neurogenic inflammation and tissue damage—the same kind of damage that occurs in human patients.

"It's a very strong acute inflammatory response that causes vessel dilation and a massive release of immune cells, cytokines, and inflammatory mediators that go into tissues," said the author. "Normally this is a protective response, but it's overexaggerated, disrupting not just the bacteria but also host cells."

 FDA-approved drugs already exist to block the triggering neuropeptides.

Aprepitant, used for nausea and vomiting, blocks substance P signaling.

Small molecules related to olcegepant or monoclonal antibodies such as fremanezumab, used for migraines, inhibit CGRP signaling.

In the mouse model, these drugs reduced inflammation and tissue damage. Somewhat surprisingly, they even reduced the burden of C. diff bacteria in the animals' intestines.'

"Recent work from others suggests that damage to intestinal cells can induce the release of nutrients that benefit C. diff," said the senior author. "The immune response disrupts the microbiome, which promotes C. diff growth. Once we tune down this host response, C. diff is less able to survive."

https://www.nature.com/articles/s41586-023-06607-2